User:Mr. Ibrahem/Orlistat

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Orlistat
Clinical data
Trade namesXenical, Alli, others
Other namesTetrahydrolipstatin
AHFS/Drugs.comMonograph
MedlinePlusa601244
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
Drug classLipase inhibitor[1]
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNegligible[2]
Protein binding>99%
MetabolismIn the GI tract
Elimination half-life1 to 2 hours
ExcretionFecal
Identifiers
  • (S)-((S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate
Chemical and physical data
FormulaC29H53NO5
Molar mass495.745 g·mol−1
3D model (JSmol)
  • O=C(O[C@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)CCCCCCCCCCC)[C@@H](NC=O)CC(C)C
  • InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1 checkY
  • Key:AHLBNYSZXLDEJQ-FWEHEUNISA-N checkY
 ☒NcheckY (what is this?)  (verify)

Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity.[3] The effectiveness is modest with people losing about 2–3 kilograms (4.4–6.6 lb) more over the course of a year.[4] It reduces the risk of type II diabetes in people who are obese similar to lifestyle changes.[5] It is taken by mouth.[3]

Common side effects include oily stools and loss of bowel control.[3] Other side effects may include allergic reactions, certain vitamin deficiencies, liver problems, kidney stones, and cholelithiasis.[3] Caution is advised during pregnancy.[1] Its primary works by preventing absorption of fats from the diet.[3] It is used together with diet and exercise.[6]

Orlistat was approved for medical use in Europe in 1998 and the United States in 1999.[3][6] It is available as a generic medication.[1] In Australia, Europe, and the United States it is available without a prescription.[7][3][8] In the United Kingdom 4 weeks of treatment costs about £25.[1] In the United States this amount costs about 80 USD.[9]

References[edit]

  1. ^ a b c d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 100. ISBN 978-0857114105.
  2. ^ Zhi J, Melia AT, Eggers H, Joly R, Patel IH (1995). "Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers". J Clin Pharmacol. 35 (11): 1103–8. doi:10.1002/j.1552-4604.1995.tb04034.x. PMID 8626884. S2CID 23618845.
  3. ^ a b c d e f g h i j "Orlistat Monograph for Professionals". Drugs.com. Archived from the original on 5 January 2021. Retrieved 9 November 2021.
  4. ^ Padwal R, Li SK, Lau DC (2004). Padwal RS (ed.). "Long-term pharmacotherapy for obesity and overweight". Cochrane Database Syst Rev (3): CD004094. doi:10.1002/14651858.CD004094.pub2. PMC 8078201. PMID 15266516.
  5. ^ Gillies, CL; Abrams, KR; Lambert, PC; Cooper, NJ; Sutton, AJ; Hsu, RT; Khunti, K (10 February 2007). "Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis". BMJ (Clinical Research Ed.). 334 (7588): 299. doi:10.1136/bmj.39063.689375.55. PMC 1796695. PMID 17237299.
  6. ^ a b "Xenical". Archived from the original on 15 April 2021. Retrieved 9 November 2021.
  7. ^ "POISONS STANDARD JUNE 2017". Federal Register of Legislation. Therapeutic Goods Administration. June 2017. Archived from the original on 13 December 2020. Retrieved 18 August 2017.
  8. ^ "Chemists to provide obesity pill". BBC News Online. 21 January 2009. Archived from the original on 23 January 2009. Retrieved 22 January 2009.
  9. ^ "Compare Alli Prices - GoodRx". GoodRx. Retrieved 9 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Orlistat&oldid=1144506297"